Illumina, Inc.
Illumina Nominates David P. King to Board of Directors
Summary
Illumina, Inc. announced on April 2, 2026, that Drs. Frances Arnold, Robert S. Epstein, and Gary S. Guthart will retire from the Board of Directors effective May 21, 2026. The Board has nominated David P. King for election as a director at the 2026 annual meeting of stockholders. Dr. King brings extensive experience in healthcare and life sciences, having served as Executive Chairman and CEO of Laboratory Corporation of America Holdings and currently holding director positions at several healthcare companies. The retirements are not due to any dispute with the company or the Board.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement